drug discovery
-
Artificial Intelligence, BioPharma
Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
-
Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds
Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company’s platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Pfizer, Flagship Team Up in $100M R&D Pact: 10 New Drugs for Unmet Needs
Pfizer and Flagship Pioneering are partnering in a drug research alliance leveraging the capabilities of the more than 40 biotech startups in the venture capital firm’s portfolio. The new partners aim to develop drugs for unmet needs, including those in broad patient populations.
-
Artificial Intelligence, BioPharma
Nvidia’s $50M Recursion Investment Starts Alliance to Scale Up in AI Drug Discovery
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
-
Pharma, Artificial Intelligence, BioPharma
Flagship Startup Emerges to Find Drugs in Promising Hunting Ground—Our Bodies
Scientists at Empress Therapeutics say molecules that co-evolved with humans over millennia are a promising source of new drugs. With its AI-driven technology platform, the Flagship Pioneering-founded startup finds them.
-
MedCity Influencers, Artificial Intelligence
AI/ML: Considerations of Healthcare’s New Frontier
Although there is uncertainty and risk, the implementation of AI with the right compliance framework and infrastructure offers an exciting opportunity to transform healthcare into a new frontier with improved patient outcomes and increased efficiency.
-
Artificial Intelligence, BioPharma
AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions
Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.
-
Flagship Startup Emerges With $50M to Send Drugs to the Right Biologic Address
Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.
-
Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics
Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Artificial Intelligence, BioPharma
Marriage of Artificial Intelligence & Biology Spawns RNA-Targeting Startup Atomic AI
Atomic AI combines artificial intelligence analysis with wet lab experiments to discover small molecules capable of drugging RNA. The startup, based on technology initially developed at Stanford, is backed by a $35 million Series A round of financing.
-
Artificial Intelligence, BioPharma
Nvidia’s AI Tech Designs Proteins Never Seen in Nature, Pointing Way to New Therapies
A collaboration between Nvidia and startup Evozyne was able to produce novel versions of a human protein never before seen in nature but with enhanced function and the same safety as native protein. The research lays the groundwork for potential new therapies for a rare inherited disorder.
-
Scripps Spinout Belharra Unveils $130M to Catch Next Big Wave of Drug Discovery
Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bind to targets previously deemed undruggable.
-
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
-
MedCity Influencers, BioPharma
Machine learning: An essential tool in the shift to risk-based quality management
Risk-based quality management is a data monitoring approach that accelerates the drug development pathway without compromising on safety – and one that is enhanced by the use of technologies such as artificial intelligence.
-
Artificial Intelligence, BioPharma
GSK Digital & Tech Executive Takes Drug-Hunting Inspiration from Outer Space
GSK is making greater use of artificial intelligence and computational techniques as part of its drug discovery efforts. Speaking during the HLTH conference in Las Vegas, executive Mike Montello likened his company’s techniques to the efforts to study and analyze images from outer space.